PARP1 and ovarian cancer: The concept of synthetic lethality, initially demonstrated in BRCA1/2-mutant breast and ovarian cancers, provides a new perspective on how defective homologous recombination (HR) renders tumor cells exceptionally vulnerable to PARP disruption [38].